Literatur
-
1
Toyka K V, Drachman D B, Pestronk A, Kao I.
Myasthenia gravis. Passive transfer from man to mouse.
Science.
1975;
190
397-399
-
2 Hohlfeld R, Melms A, Schneider C, Toyka K V, Drachman D B. Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg). Neurological disorders - course and treatment. Amsterdam: Elsevier 2003: 1341-1362
-
3
Hill M.
The neuromuscular junction disorders.
J Neurol Neurosurg and Psychiatry.
2003;
74 (Suppl II)
32-37
-
4
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A.
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Nat Med.
2001;
7
365-368
-
5
Vincent A, Bowen J, Newsom-Davis J, McConville J.
Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets.
Lancet Neurology.
2003;
2
99-1065
-
6
Masaoka A, Monden Y, Nakahara K, Tanioka T.
Follow-up study of thymoma with special reference to their clinical stages.
Cancer.
1981;
48
2485-2492
-
7 Hohlfeld R, Wekerle H. The immunopathogenesis of myasthenia gravis. In: Engel AG (Hrsg.). Myasthenia gravis and myasthenic syndromes. Oxford: Oxford University Press 1999: 87-110
-
8
Buckley C, Newsom-Davis J, Willcox N, Vincent A.
Do titin and cytokine antibodies predict thymoma and thymoma recurrence?.
Neurology.
2001;
57
1579-1582
-
9
Batocchi A P, Majolini L, Evoli A, Lino M M, Minisci C, Tonali P.
Course and treatment of myasthenia gravis during pregnancy.
Neurology.
1999;
52
447-452
-
10
Osserman K E, Genkins G.
Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.
Mt Sinai J Med.
1971;
38
497-537
-
11
Besinger U A, Toyka K V, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A.
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.
Neurology.
1983;
33
1316-1321
-
12
Burns T M, Russell J A, LaChance D H, Jones H R.
Oculobulbar involvement is typical with Lambert-Eaton Myasthenic Syndrome.
Ann Neurol.
2003;
53
270-273
-
13
Schneider C, Reiners K.
Elektrophysiologische Diagnostik neuromuskulärer Übertragungsstörungen.
Klin Neurophysiol.
2000;
31
122-135
-
14
Lindstrom J.
An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.
Clin Immunol Immunopathol.
1977;
7
36-43
-
15
Marienhagen J, Schalke B, Aebert H, Held P, Eilles C, Bogdahn U.
Somatostatin receptor scintigraphy in thymoma imaging method and clinical application.
Pathol Res Pract.
1999;
195
575-581
-
16
Michels M.
Hohlfeld R, Hartung HP, Heininger K, Besinger UA, Toyka KV. Myasthenia gravis: discontinuation of longterm azathioprine.
Ann Neurol.
1988;
24
798
-
17
Drachman D B, Jones R J, Brodsky R A.
Treatment of refractory myasthenia gravis: Rebooting with high dose cyclophosphamide.
Ann Neurol.
2003;
53
29-34
-
18
Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B.
Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
Neurology.
2001;
56
97-99
-
19
Schneider C, Gold R, Reiners K, Toyka K V.
Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Eur Neurol.
2001;
46
79-82
-
20
Heininger K, Hartung H P, Toyka K V, Gaczkowski A, Borberg H.
Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels.
Ann N Y Acad Sci.
1987;
505
898-900
-
21
Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C.
Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.
Ann Neurology.
1997;
41
789-796
-
22
Flachenecker P, Taleghani B M, Gold R, Grossmann R, Wiebecke D, Toyka K V.
Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.
Transfus Sci.
1998;
19 (Suppl)
43-46
-
23
Gronseth G S, Barohn R J.
Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review).
Neurology.
2000;
55
7-15
-
24
Mayer S A.
Intensive care of the myasthenic patient.
Neurology.
1997;
48 (Suppl.)
570-575
-
25
Thomas C E, Mayer S A, Gungor Y, Swarup R, Webster E A, Chang I, Branagan T H, Fink M E, Rowland L P.
Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation.
Neurology.
1997;
48
1253-1260
Dr. C. Schneider-Gold
Neurologische und Neurochirurgische Klinik, Julius-Maximilians-Universität Würzburg
Josef-Schneider-Str. 11
97080 Würzburg
Email: christiane.schneider-gold@uni-würzburg.de
